February 3, 2026
Mirum Pharmaceuticals SVP discusses the Bluejay acquisition, bolstering their rare disease pipeline with a focus on patient-centric M&A strategy.
February 2, 2026
AI enhances med comms efficiency, but human expertise remains essential for accuracy, strategic insight, and maintaining trust in scientific rigor.
January 30, 2026
Biopharma M&A rebounds in 2026 with a 'proof over promise' mindset. Expect disciplined, innovation-focused deals despite market uncertainties.
January 23, 2026
JPM26 was surprisingly quiet on mega-deals but loud on AI hype. Key themes: biotech funding woes, China's rise, and new M&A mindsets.
January 16, 2026
FDA drug approvals dipped to 46 in 2025 amid turmoil but surged in H2. European firms outpaced US counterparts, with a focus on rare diseases.
January 12, 2026
Beyond the buzzword: How integrating the patient voice transforms pharma strategy, from evidence generation to market access and communication.
December 19, 2025
Biopharma in 2026 faces a new reality shaped by US policy shifts, from federal funding cuts and FDA turmoil to global trade deals.
December 8, 2025
Walgreens leverages its massive real-world data to provide pharma with actionable insights, improving patient access, adherence, and outcomes.
